Q16552 (IL17_HUMAN) Homo sapiens (Human)
Interleukin-17A UniProtKBInterProSTRINGInteractive Modelling
155 aa; Sequence (Fasta)
Available Structures
34 Experimental Structures
| Description | PDB ID | Oligo-state | Range | Seq id (%) | Ligands | |
|---|---|---|---|---|---|---|
| Structure of the IL-17A-IL-17RA binary complex |
Heteromer Q96F46; | 100.0 | 1×NAG; 7×NAG; | |||
| Structure of the IL-17A-IL-17RA-IL-17RC ternary complex |
Heteromer Q8NAC3; Q96F46; | 100.0 | 1×NAG; 9×NAG; | |||
| Computationally designed functional antibody |
Heteromer | 100.0 | ||||
| Crystal Structure of IL-17A/Fab6785 complex |
Heteromer | 99.16 | 5×GOL; 1×CL; 5×SO4; | |||
| Crystal Structure of human IL-17A in complex with IL-17RA and IL-17RC |
Heteromer Q8NAC3; Q96F46; | 98.25 | 8×NAG; | |||
| Crystal Structure of Human IL-17AF |
Heteromer Q96PD4; | 100.0 | 1×NAG; | |||
| Structure of interleukin 17a in complex with il17ra receptor |
Heteromer Q96F46; | 98.08 | 1×NAG; 1×NAG; 1×NAG; | |||
| Crystal Structure of the 11.003 Fab in complex with human IL-17A |
Heteromer | 99.01 | 2×GOL; | |||
| Crystal Structure of scFv CAT2200 LH in complex with IL-17A |
Heteromer | 97.96 | 2×SO4; | |||
| Complex IL-17A/anti-IL-17A-76 |
Heteromer | 98.09 | 2×GOL; 2×CL; 2×SO4; | |||
| Crystal Structure of human IL-17AF in complex with human IL-17RA |
Heteromer Q96F46; Q96PD4; | 100.0 | 1×NAG; 1×NAG; | |||
| Binding site elucidation and structure guided design of macrocyclic IL-17A antagonists |
Heteromer | 100.0 | 1×63O; | |||
| Inhibiting complex IL-17A and IL-17RA interactions with a linear peptide |
Heteromer | 97.78 | ||||
| Crystal Structure of spFv CAT2200 LH in complex with IL-17A |
Heteromer | 98.0 | 1×CL; | |||
| Binding site elucidation and structure guided design of macrocyclic IL-17A antagonists |
Heteromer | 100.0 | 1×63Q; | |||
| IL-17A in complex with the humanized antibody HB0017 |
Heteromer | 100.0 | 7×MLA; 4×ACY; | |||
| Inhibiting complex IL-17A and IL-17RA interactions with a linear peptide |
Heteromer | 100.0 | ||||
| Fab antigen complex |
Heteromer | 100 | ||||
| Binding site elucidation and structure guided design of macrocyclic IL-17A antagonists |
Heteromer | 100.0 | 1×63P; | |||
| Structure of IL-17A in complex with a potent, fully human neutralising antibody |
Heteromer | 100.0 | 4×SO4; | |||
| Fab antigen complex |
Heteromer | 100 | ||||
| IL-17A in complex with peptide | homo-2-mer | 98.13 | 4×EDO; | |||
| IL17A homodimer bound to Compound 7 | homo-2-mer | 100.0 | 2×U5Q; | |||
| IL17A homodimer bound to Compound 6 | homo-2-mer | 100.0 | 2×U5X; 1×GOL; | |||
| Crystal structure of IL-17A in complex with compound 18 | homo-2-mer | 98.99 | 1×A1IDT; | |||
| IL17A homodimer bound to Compound 5 | homo-2-mer | 100.0 | 2×U6C; | |||
| IL17A homodimer complexed to Compound 23 | homo-2-mer | 98.96 | 2×XCE; | |||
| IL17A homodimer bound to Compound 10 | homo-2-mer | 99.02 | 1×U5I; | |||
| Crystal structure of IL-17A in complex with compound 26 | homo-2-mer | 98.98 | 1×A1IDS; | |||
| Human interleukin 17A | homo-2-mer | 97.92 | ||||
| IL-17A in complex with small molecule modulators | homo-2-mer | 100.0 | 1×RMK; | |||
| Crystal structure of human IL-17A cytokine in complex with macrocycle | homo-2-mer | 97.92 | 1×UTF; | |||
| IL-17A in complex with small molecule modulators | homo-2-mer | 100.0 | 1×RMQ; | |||
| IL17A complexed to Compound 7 | monomer | 100.0 | 1×XCW; 1×CL; | |||
1 SWISS-MODEL model
| Template | Oligo-state | QMEAN | Range | Ligands | Trg-Tpl Seq id (%) | |
|---|---|---|---|---|---|---|
| 5n7w.1.E | monomer | 0.67 | 100.00 | |||